Cholesterol and triglycerides is the main area connected here, and any felt benefit should be read together with the human evidence base.
Human evidence exists, but it is mostly in patient or disease contexts, so the score is handled conservatively.
Representative tier calculated from paper evidence that passed the collection audit.
The representative ingredient tier is calculated from these target-level evidence groups.
Potential benefit studied in Blood lipids. These findings come from a defined study population, so everyday effects may differ.
This score reflects the strength of this benefit group. The ingredient tier also considers paper count, repetition, population, and study context.
This card is closer to a measured biomarker or lab outcome than a directly felt user benefit. These findings come from a defined study population, so everyday effects may differ.
This score reflects the strength of this benefit group. The ingredient tier also considers paper count, repetition, population, and study context.
These findings come from sperm, semen, or hormone markers such as testosterone, LH, FSH, and inhibin B. They are closer to research measurements than a directly felt benefit. These findings come from a defined study population, so everyday effects may differ.
This score reflects the strength of this benefit group. The ingredient tier also considers paper count, repetition, population, and study context.
These findings come from stress response, cortisol, anxiety, or sleep outcomes. They may mix felt benefits with physiological markers.
This score reflects the strength of this benefit group. The ingredient tier also considers paper count, repetition, population, and study context.
Potential benefit studied in Women's health. These findings come from a defined study population, so everyday effects may differ.
This score reflects the strength of this benefit group. The ingredient tier also considers paper count, repetition, population, and study context.
This is based on lab markers such as blood levels, deficiency correction, or absorption. Read it separately from directly felt outcomes.
This score reflects the strength of this benefit group. The ingredient tier also considers paper count, repetition, population, and study context.
Standalone side-effect signals and combination cautions are listed separately.
The group showed a positive signal, but individual contributions are hard to isolate. Not a stack recommendation.
Paper IDs and full lists are private. Only study types and summaries are shown.
CoQ10 supplementation does not reduce muscle pain in patients with statin myalgia and only 36% of patients complaining of statin myalgia develop symptoms during a randomized, double-blind crossover of statin vs placebo.
Pretreatment with CoQ10 improves ovarian response to stimulation and embryological parameters in young women with poor ovarian reserve in IVF-ICSI cycles and further work is required to determine whether there is an effect on clinical treatment endpoints.
This review focused on recent advances in CoQ10 supplementation, its role as an antioxidant, and the clinical implications that this entails in the treatment of chronic diseases, in particular cardiovascular diseases, kidney disease, chronic obstructive pulmon
A meta-analysis of RCTs suggests that some dietary supplements could beneficially modulate sperm quality parameters and affect male fertility.
Three‐month supplementation with CoQ10 in OAT infertile men can attenuate oxidative stress in seminal plasma and improve semen parameters and antioxidant enzymes activity.
The importance of individually adapted selection of best formulations to reach the highest bioavailability of CoQ10 in humans is highlighted, as some of the participants showed high and others lower capacity to reach high increase of Co Q10 in blood, indicatin